Kornimate/medical-research-clean huggingface dataset:
full-endoscopic vs open discectomy for the treatment of symptomatic lumbar herniated disc

Conditions: Lumbar Disc Herniation

Summary: the purpose of this study is to compare the clinical and radiographic outcomes of full endoscopic lumbar discectomy versus open lumbar decompression for the treatment of lumbar herniated discs in which the patient's leg pain is greater than back pain.

the study will be performed utilizing a prospective multi-center randomized model. approximately 7 centers will be included in the study as listed above. patients will be informed of clinical trial and asked if they would like to participate. patients are informed that participation is optional. patients may withdraw from study any time prior to or after surgery. patients will be randomized 2:1 ratio endoscopic:open surgery. both the endoscopic and open surgical techniques are utilized in standard of care. if a subject requires an open surgery approach (based on the surgeons assessment at the time of surgery pre or post incision) after they are randomized to the endoscopic arm, they will be switched to the open arm and included in the open crossover arm of the study. study procedures will occur at the following time points; pre-op, 6 wk, 3 mon, 6 mon, 1 yr and 2 yr follow-up.subjects will complete questionnaires that assess pain level and location, functional capacity, work and health status, medication usage and duration of symptoms.

Eligibility criteria:
inclusion criteria: 1. patient equal to or greater than 18 years old. 2. patients with single level para-central herniated discs from l1-s1. 3. vas (visual analog scale) leg \> 40 mm. 4. leg pain must be greater than back pain. 5. minimum 6 weeks conservative treatment unless motor strength u\< u4/5 and or deteriorating neurologic function. exclusion criteria: 1. lateral/subarticular, far lateral disc herniations 2. multi-focal (multi modal) disc herniations 3. symptomatic multiple level disc herniations 4. active infection either spinal or otherwise 5. prior history of lumbar spinal infection at any level 6. spinal tumor in lumbar region 7. dynamic (any grade) or fixed spondylolisthesis more than 3mm 8. disc extrusion that is more superior than most inferior aspect of superior pedicle above index disc level 9. disc extrusion that is more inferior than the middle aspect of inferior pedicle below the index disc level 10. presence of unilateral or bilateral pars inter articularis defects (spondylolysis) 11. disc herniation which is significantly calcified 12. contra-lateral leg pain u\>40 mm 13. history of peripheral diabetic neuropathy 14. significant central stenosis with history of neurogenic claudication 15. pregnancy 16. facet cyst on symptomatic side 17. cauda equina syndrome past or present 18. patients cannot have had prior lumbar surgery including idet (intradiscal electrothermal therapy) or other percutaneous surgical procedures. 19. significant vascular claudication 20. history of radiation to the spinal column 21. history of malignancy of any type within 2 years of consideration of enrollment
cvp-guided aquapheresis for the treatment of acute congestion in heart failure

Conditions: Heart Failure

Summary: the number of patients with acute congestion on chronic heart failure is increasing. ultrafiltration has recently been proposed as an alternative approach for the stabilization of volume balance, especially in patients with imminent diuretic resistance. there is increasing evidence that ultrafiltration may relief cardiac congestion with lesser effects on blood pressure and activation of renin angiotensin system, respectively . however, recent studies revealed conflicting results: demonstration the superiority of ultrafiltration in comparison to diuretic treatment, and a lack of evidence of benefit, as well as an excess of adverse events with ultrafiltration. aquapheresis with adapted ultrafiltration rate guided by central venous pressure is safer than aquaphesis with a constant ultrafiltration with comparable effectiveness


Eligibility criteria:
inclusion criteria: * patients with chronic heart failure scheduled for lvad * indication for cvvh/aquapheresis exclusion criteria: * renal disease (gfr \<20 ml / min)
performance evaluation of different daily disposable silicone hydrogel contact lenses

Conditions: Myopia

Summary: the goal of this study is to compare the performance of two daily disposable silicone hydrogel contact lenses.

this study is a prospective, bilateral eye, double masked, randomized, 1-week crossover, daily wear design involving two different daily disposable lens types. each lens type will be worn for approximately one week.

Eligibility criteria:
inclusion criteria: 1. is between 18 and 35 years of age (inclusively) and has full legal capacity to volunteer; 2. has read and signed an information consent letter; 3. self-reports having a full eye examination in the previous two years; 4. anticipates being able to wear the study lenses for at least 8 hours a day, 7 days a week; 5. is willing and able to follow instructions and maintain the appointment schedule; 6. habitually wears soft contact lenses, for the past 3 months minimum; 1. no more than 1/3 of participants should be habitual wearer of myday or myday energys 2. no more than 1/3 of participants should be habitual wearer of acuvue® oasys max 1-day or acuvue® oasys 1-day. 7. has refractive astigmatism no higher than -0.75dc in each eye; 8. can be fit and achieve binocular distance vision of at least 20/30 snellen (available lens parameters are sphere -1.00 to -6.00d, 0.25d steps). exclusion criteria: 1. is participating in any concurrent clinical or research study; 2. has any known active ocular disease and/or infection that contraindicates contact lens wear; 3. has a systemic condition that in the opinion of the investigator may affect a study outcome variable; 4. is using any systemic or topical medications that in the opinion of the investigator may affect contact lens wear or a study outcome variable; 5. has known sensitivity to the diagnostic sodium fluorescein used in the study; 6. self-reports as pregnant, lactating or planning a pregnancy at the time of enrolment; 7. has undergone refractive error surgery or intraocular surgery.
the effect of bariatric surgery on hepatic metabolism in non-alcoholic fatty liver disease

Conditions: Non-Alcoholic Fatty Liver Disease

Summary: the purpose of this study is to investigate the mechanisms underlying bariatric surgery-induced resolution of non-alcoholic fatty liver disease.

bariatric surgery is one of the few currently available treatment options for non-alcoholic fatty liver disease (nafld). in most cases, nafld is entirely ameliorated after the surgery but in some individuals, the disease may persist or even progress. the mechanisms underlying the bariatric surgery-mediated resolution of nafld and the heterogeneity in the response remain poorly understood. in this study, the investigators will examine the metabolic effects of bariatric surgery-induced resolution of nafld. to this end, study subjects who have previously undergone bariatric surgery and metabolic studies will be invited for a follow-up visit for physical examination, evaluation of body composition with bioelectrical impedance and quantification of liver stiffness using non-invasive transient elastography and magnetic resonance elastography (mre). body fat composition will be evaluated by magnetic resonance imaging (mri) and hepatic lipid content will be measured with magnetic resonance spectroscopy (mrs). in addition, 1h nuclear magnetic resonance (nmr) metabolomic analyses will be carried out from plasma samples collected both before and after bariatric surgery. insulin resistance will be assessed using the homa-ir index and the genotypes in disease-modifying genes including pnpla3, tm6sf2, mboat7, marc1 and hsd17b13 will be assessed. liver biopsies were obtained at the time of bariatric surgery and, in individuals with a clinical indication, a follow-up liver biopsy will be obtained.

Eligibility criteria:
inclusion criteria: * participants must have undergone bariatric surgery and previously participated in a metabolic study in our research group. * participants must be able to communicate meaningfully with the investigator and must be legally competent to provide written informed consent. * age range from 18-75 years. exclusion criteria: * no claustrophobia or metal implants to allow magnetic resonance spectroscopy. * no pregnancy or lactation in women.

Keywords: fatty liver liver diseases digestive system diseases bariatric surgery
the reliability of myotonometer in evaluating the muscle tone and biomechanical properties of the forearm muscles

Conditions: Muscular Tone; Viscoelasticity

Summary: the primary aim of this study was to evaluate the intra-rater and inter-rater reliability of myotonpro in measuring muscle tone and mechanical properties of the wrist extensor and flexor muscles in healthy young adults. the secondary aim is to examine whether grip strength has any effect on muscle tone and biomechanical properties.


Eligibility criteria:
inclusion criteria: * age≥18 years * body mass index \< 30 kg/meter square * having no upper extremity injuries * willing and able to provide the written informed consent for the study exclusion criteria: * use of medication that will affect muscle tone * history of lateral or medial epicondylitis, trauma (elbow, hand or wrist), cervical radiculopathy, peripheral neuropathy or nerve injury (axillary, median, ulnar, radial, musculocutaneous), systemical diseases, muscle disorders (e.g. genetic diseases, neuromuscular disorders)

Keywords: elasticity hardness forearm muscles
development of transdiagnostic single-session treatment

Conditions: Anxiety Disorders; Depression; Stress Disorder

Summary: the goal of this clinical trial is to test a single session treatment program in primary care patients with anxiety and/or depression and/or stress-related issues. the main questions it aims to answer is: * will the transdiagnostic treatment program decrease symptoms of depression/anxiety/stress? * will the transdiagnostic treatment program decrease transdiagnostic risk factors? * will the transdiagnostic treatment program decrease the measured risk factors equally? * will the transdiagnostic treatment program impact patients with anxiety, depression or stress disorders equally? * will the transdiagnostic treatment program have long term (6 months post-treatment) effect on transdiagnostic risk factors? * will the transdiagnostic treatment program have long term (6 months post-treatment) effect on anxiety, depression, or stress-symptoms? * have the participants been able to generalize the skills taught in the program(qualitative)? * within group that were treated with single-session treatment and recieved additional care before follow-up, was there a difference in outcome?

the study investigates the effect of a single-session, 4 hour, transdiagnostic treatment for primary care patientst with depression, anxiety or stress. the treatment includes, interoceptive exposure, behavioral activation, mindfulness, defusion and psycho-education about emotions. the study is conducted in a clinical setting in northern sweden and follows up results at 3 weeks and 6 months post treatment.

Eligibility criteria:
inclusion criteria: * meet the criteria for anxiety, mood disorder, or stress diagnosis * symptoms are mild to moderate in severity exclusion criteria: * already in ongoing psychotherapy * within a month commenced pharmaceutical treatment that will likely impact mood or psychological functioning and is not deemed to be on a stable dose * has a comorbid personality disorder * has a risk of suicide deemed other than low * has other severe psychological disorders outside the scope of primary care * is in a severely stressful social situation deemed incompatible with psychotherapy

Keywords: transdiagnostic single-session
safety and efficacy of td0025 (rocket1h) for treatment of erectile dysfunction

Conditions: Erectile Dysfunction

Summary: the purpose of this study is to identify the optimal dose(s) of td0025 for treatment of erectile dysfunction (phase ii) and to investigate if treatment of erectile dysfunction with the optimal dose of td0025 taken as needed over one month is non-inferior than sildenafil citrate taken as needed over one month (phase iii)


Eligibility criteria:
main inclusion criteria: * history of erectile dysfunction (ed) of at least 1 month duration. * anticipate having the same adult female sexual partner during the study. * agree not to use any other treatment for ed and to participate in recording responses to questionnaires and other instruments used in this study. * sign the informed consent form main exclusion criteria: * ed caused by other primary sexual disorders, history of radical prostatectomy or other pelvic surgery with subsequent failure to achieve any erection, or history of penile implant or clinically significant penile deformity * ed caused by untreated or inadequately treated endocrine disease * current treatment with doxazocin, nitrates, cancer chemotherapy, or anti-androgens * severe renal or hepatic impairment, history of malignant hypertension * presence or history of specific heart conditions

Keywords: sexual dysfunction physiological sexual dysfunctions psychological sexual and gender disorders sildenafil
healthful seafood consumption for sensitive populations

Conditions: Infant Brain Health

Summary: fish can provide pregnant women with omega-3 fatty acids for fetal brain development but some fish contains high levels of mercury which is detrimental to fetal brain development. the hypothesis is that women who have previously consumed high mercury fish can reduce the mercury level in their bodies and improve their omega-3 levels in three months by eating fish that is high in omega-3 fatty acids and low in mercury.

exposure to methylmercury, a developmental toxicant found primarily in fish. fish is nutritionally important for providing long chain omega-3 fatty acids that are important for perinatal health. since maternal transfer of mercury and omega-3 fatty acids are the primary routes for fetal (placental transfer) or infant (maternal milk) exposure, there is a critical need to develop specific advice for childbearing-aged women based upon the 2004 dietary guidelines advisory committee's recommended intake i.e., consume 8 ounces of fish per week. this clinical trial investigates whether weekly consumption of selected fish species for 12 weeks can improve plasma concentrations of the omega-3 fatty acids (eicosapentaenoic acid (epa) and docosahexaenoic acid (dha)) while reducing hair or blood mercury concentrations.

Eligibility criteria:
inclusion criteria: * hair mercury levels equal to or greater than 0.8 ppm exclusion criteria: * pregnant or planning to become pregnant in the next 3 months * nursing

Keywords: fish mercury omega-3 fatty acids infant brain development pregnancy nursing mother dietary recommendations hair mercury blood mercury recommendations for pregnant or nursing women infant brain health
impact of per oral pyloromyotomy (pop) on glycemic control in diabetes

Conditions: Diabetes Mellitus; Gastroparesis With Diabetes Mellitus; Gastroparesis

Summary: this study will assess changes in glycemic control in 40 patients with diabetes who undergo per-oral pyloromyotomy (pop) for medically refractory gastroparesis.

this will be a prospective study using hba1c values and continuous glucose monitoring (cgm) to assess changes in glycemic control in patients with diabetes who undergo per-oral pyloromyotomy (pop) for medically refractory gastroparesis. the study cohort will consist of 40 patients with poor glycemic control who undergo pop. the investigators propose a prospective cohort study using cgm to compare glycemic profiles before and after pop in patients with diabetic gastroparesis. the investigators hypothesize that patients will have improvement in glycemic control and reduced variation in blood glucose levels (% time in hypo/hyperglycemia) after undergoing pop. these results will aid in clinical decision making, and may indicate an earlier need for endoscopic intervention in patients with uncontrolled diabetes and gastroparesis.

Eligibility criteria:
inclusion criteria: 1. patients 18 years of age and older 2. patients with gastroparesis with an average hba1c\> 7.5% over the past 3 months 3. patient that have a diagnosis of gastroparesis established by documented delayed gastric emptying by either a wireless motility capsule study or a nuclear gastric emptying study, with no evidence of gastric obstruction. 4. patients are able to complete all study requirements exclusion criteria: 1. patients \<18 years of age 2. patients with gastroparesis with an average hba1c\< 7.5% over the past 3 months 3. patients unable or refuse to complete the study requirements 4. patients who are unable or refuse to wear a cgm sensor 5. patients with insulin pumps 6. patients who already use a cgm
comparison of the effect of two different interventions

Conditions: To Compare the Effect of Two Different Nonpharmacological Methods on Pain and Fear During Peripheral Intravenous Catheterization

Summary: the goal of this clinical trial is to compare the effect of two different non-pharmacologic interventions with the control group in reducing pain due to peripheral intravenous catheterization application in children aged 5-12 years. hypotheses: h1: pain level differs in the group that received pik with palm stimulator compared to the control group. h2: the level of fear in the group with pik application with palm stimulator differs from the control group. h3: satisfaction level is different in the group with pik application with palm stimulator compared to the control group. h4: the pain level differs in the group that received pik application by watching cartoons compared to the control group. h5: the level of fear is different in the group that received pik application by watching cartoons compared to the control group. h6: satisfaction level is different in the group that received pik application by watching cartoons compared to the control group. h7: pain level is different in the palm stimulator pik group compared to the cartoon group. h8: the level of fear is different in the palm stimulator pik group compared to the cartoon group. h9: the satisfaction level in the group with pik application with palm stimulator is different from the cartoon group. h10: pik application time is different in the palm stimulator group compared to the control group. h11: pik application time is different in the cartoon group compared to the co

1. to measure the pain and fear levels of children by placing a palm stimulator on their palms during pik application 2. measuring pain and fear levels by watching cartoons to children during pik application

Eligibility criteria:
inclusion criteria: 1. voluntary participation in the study, 2. pediatric patients for whom written and verbal consent has been obtained from the parent, 3. pediatric patients for whom verbal consent was obtained, (3) not under the influence of sedative/anticonvulsant/analgesic drugs, (4) pediatric patients aged 5-12 years, (5) pediatric patients who can communicate, understand, and carry out commands and are not dependent on technological devices. exclusion criteria: 1. not volunteering to participate in the study, 2. more than one pik attempt, 3. children with a chronic, acute, or life-threatening illness.

Keywords: pain fear children distraction palm stimulator cartoon peripheral intravenous catheterization cannulation
coffee and real-time atrial and ventricular ectopy

Conditions: Premature Atrial Contractions; Premature Ventricular Contractions

Summary: atrial fibrillation (af) and heart failure (hf) are morbid, costly, and incompletely understood diseases that have reached epidemic proportions worldwide. a dose-dependent relationship exists between premature atrial and ventricular contractions (pacs and pvcs) and development of af and hf, respectively. identifying and understanding the mechanisms of additional modifiable risk factors for ectopy has the potential to markedly reduce the healthcare burden of these diseases. in considering how to modify the prevalence of these ectopic beats, the investigators believe common exposures in daily life are prime candidates. current guidelines suggest that caffeine may be an important trigger for frequent ectopy, although large population-based studies have not demonstrated an association between caffeine consumption and development of clinically significant arrhythmias. no study has employed an actual randomization intervention to assess the effects of caffeine on cardiac ectopy. utilizing the eureka platform, the investigators plan to utilize the n-of-1 strategy to rigorously investigate the real-time effect of caffeine intake on ectopy.

this study is designed as a n to 1 randomized trial, where each participant will be randomized to consume or abstain from coffee each day of a 14 day monitoring period. participants will wear an automatically recording electrocardiographic monitor (zio® xt patch), continuous glucose monitor (dexcom g6), and a fitness tracker (fitbit inspire) while utilizing eureka-a mobile application. we will compare participant self-report of caffeine consumption, glucose monitoring, fitness levels, sleep health, and heart rhythm data in order to better understand the relationship between acute caffeine consumption and heart rhythm changes. participants will also be genotyped for caffeine metabolism-related snps. a total of 100 participants will be enrolled at the ucsf study site.

Eligibility criteria:
inclusion criteria: 1. are age 18 or older 2. have a smartphone 3. are able to use the eureka mobile application 4. are willing to provide a saliva sample for genetic processing 5. drink coffee or coffee-based products at least once a year 6. are willing to abstain from coffee, caffeinated products, or minimally caffeinated products (decaffeinated coffee) for at least 2 days when instructed exclusion criteria: 1. have a history of atrial fibrillation, heart failure 2. have an icd or pacemaker 3. have treatment with beta blockers, non-dihydropyridine calcium channel blockers, or vaughn-williams class 1 or 3 antiarrhythmic medications 4. have a medical reason to avoid coffee

Keywords: caffeine coffee arrhythmias palpitations cardiac ectopy pacs pvcs